Clinical trial
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
NCT02638805 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
- Lead sponsor
- Intarcia Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- October 31, 2017
- Enrollment
- 136 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.